Celcuity (NASDAQ:CELC) Reaches New 1-Year High – Time to Buy?

30 Jan 2026, 01:21 by Michael Walen · The Markets Daily

Shares of Celcuity, Inc. (NASDAQ:CELC – Get Free Report) reached a new 52-week high during trading on Tuesday . The company traded as high as $120.32 and last traded at $115.5760, with a volume of 155148 shares traded. The stock had previously closed at $114.01.

Wall Street Analyst Weigh In

CELC has been the topic of several research analyst reports. Wolfe Research assumed coverage on shares of Celcuity in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $110.00 price objective on the stock. Jefferies Financial Group increased their price target on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Wells Fargo & Company assumed coverage on shares of Celcuity in a research report on Friday, December 12th. They set an “overweight” rating and a $126.00 price objective for the company. Stifel Nicolaus upped their target price on Celcuity from $68.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Finally, HC Wainwright reissued a “neutral” rating and set a $94.00 price target (up from $77.00) on shares of Celcuity in a report on Monday, November 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Celcuity presently has an average rating of “Moderate Buy” and a consensus target price of $105.25.

View Our Latest Stock Report on CELC

Celcuity Trading Down 2.1%

The firm has a market capitalization of $5.19 billion, a P/E ratio of -30.55 and a beta of 0.25. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The firm has a 50 day moving average of $104.00 and a 200-day moving average of $71.07.

Celcuity (NASDAQ:CELC – Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.13. On average, equities research analysts predict that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Richard E. Buller sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $105.69, for a total transaction of $317,070.00. Following the completion of the sale, the director owned 6,760 shares of the company’s stock, valued at approximately $714,464.40. This represents a 30.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the transaction, the director directly owned 90,000 shares in the company, valued at $10,802,700. This trade represents a 18.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 26,900 shares of company stock valued at $3,094,917 in the last ninety days. 15.78% of the stock is currently owned by company insiders.

Institutional Trading of Celcuity

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Celcuity by 10.7% in the 4th quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock valued at $227,351,000 after acquiring an additional 220,386 shares during the last quarter. NBC Securities Inc. acquired a new position in Celcuity in the 4th quarter worth about $99,000. Arizona State Retirement System bought a new position in Celcuity in the fourth quarter valued at about $359,000. M&T Bank Corp raised its position in Celcuity by 91.7% in the fourth quarter. M&T Bank Corp now owns 7,835 shares of the company’s stock valued at $781,000 after purchasing an additional 3,747 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Celcuity during the fourth quarter valued at about $551,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

(Get Free Report)

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.